Pfzizer's Geodon fares well vs placebo and Zyprexa

Pfizer, the world's largest drugmaker, says that its antipsychotic Geodon (ziprasidone) produces a significant improvements in patients with bipolar mania experienceing either manic or mixed episodes.

A study published in the August issue of the Journal of Clinical Psychopharmacology confirms the rapid onset of efficacy and sustained improvement seen in previous placebo-controlled trials of the drug, the firm stated.

The three-week, double-blind, multicenter, 206-patient study found that the average change from baseline to the end of the evaluation was significantly greater for Geodon than for placebo on the primary efficacy measure, the Mania Rating Scale.